(P036) The Significance of Different Dose Fractionations in the Management of Optic Nerve Sheath Meningioma

Publication
Article
OncologyOncology Vol 28 No 1S
Volume 28
Issue 1S

Optic nerve sheath meningiomas (ONMs) typically present with unilateral vision loss, visual disturbance, and/or eye pain or pressure. ONMs are generally not amenable to surgery due to morbidity, visual deterioration. For this reason, radiation is often used as primary treatment.

Veronica A. Finnegan, MD, Seung Hahn, MD, Anna Shapiro, MD, Luis Mejico, MD; SUNY Upstate Medical University

Background: Optic nerve sheath meningiomas (ONMs) typically present with unilateral vision loss, visual disturbance, and/or eye pain or pressure. The diagnosis is usually made by clinical and imaging findings without biopsy. ONMs are generally not amenable to surgery due to morbidity, visual deterioration. For this reason, radiation is often used as primary treatment. Different dose fractionations have been used, without clear consensus on optimal treatment. The number of fractions can also be influenced by accessibility to treatment centers and is a significant factor for patients in rural areas treated with conventional-dose fractionation, which requires over 5 weeks of treatment.

Materials and Methods: A retrospective review of patients treated with radiation therapy (RT) for ONMs was performed to analyze tumor control, symptom improvement, and treatment complications according to different dose fractionations. Patients had documented vision testing before and after treatment, which was performed by a neuro-ophthalmologist.

Results: Data were collected on 8 patients, 2 of whom had bilateral disease, for a total of 10 cases treated for ONM between 2006 and 2012. Vision loss was the presenting symptom in eight cases, one patient had eye pain, and the other was asymptomatic and was found to have an abnormal eye exam with increased optic nerve pressure. The patient who was asymptomatic had biopsy consistent with meningioma. Median follow-up was 43 months. Six optic nerve tumors were treated by conventional fractionation (≤ 2 Gy/fraction to a total dose of 45–54 Gy). They were considered standard fractionation. Four cases were treated with hypofractionated radiotherapy using 25 Gy in five fractions. All patients had local control based on the most recent imaging with MRI. In follow-up vision testing by neuro-ophthalmologic evaluation, 6 of 10 eyes achieved long-term vision improvement. Three patients had stable vision, and one had worse. With conventional fractionation, three of six had improvement, two were stable and one was worse. For the hypofractionated radiotherapy group, four of four had initial improvement, and three had long-term improvement. One patient developed radiation retinopathy 3 years after treatment, resulting in vision loss. In this case, the retina received full dose due to extension of the tumor. Six of nine patients, excluding the one who was asymptomatic, had resolution of subjective symptoms. Vision in the contralateral eye was unaffected in the majority of cases and actually improved in one patient, possibly due to radiotherapy to the area of involvement of the optic chiasm.

Conclusion: RT for ONM is an effective treatment to prevent visual deterioration and often improves visual loss that has already happened. Our study indicates that hypofractionated radiation is at least as effective as conventional radiation in preventing visual loss but seems to be more effective for improving visual changes caused by ONM. Hypofractionated radiation can be safely applied to patients with limited access to radiation centers. This should be further tested in a nationwide large-scale study in the future.

Articles in this issue

(P113) Age and Marital Status Are Associated With Choice of Mastectomy in Patients Eligible for Breast Conservation Therapy
(P112) Single-Institution Experience With Intrabeam IORT for Treatment of Early-Stage Breast Cancer
(P110) Breast Cancer Before Age 40: Current Patterns in Clinical Presentation and Local Management
(P111) Accelerated Partial-Breast Irradiation With Multicatheter High-Dose-Rate Brachytherapy: Feasibility and Results in a Private Practice Cohort
(P115) Breast Cancer Laterality Does Not Influence Overall Survival in a Large Modern Cohort: Implications for Radiation-Related Cardiac Mortality
(P117) Anatomical Variations and Radiation Technique for Breast Cancer
(P116) Bilateral Immediate DIEP Reconstruction and Postmastectomy Radiotherapy: Experience at a Tertiary Care Institution
(P118) Metadherin Overexpression Is Associated With Improved Locoregional Control After Mastectomy
(P119) Effect of Economic Environment on Use of Postlumpectomy Radiation Therapy for Stage I Breast Cancer
(P120) Immediate Versus Delayed Reconstruction After Mastectomy in the United States Medicare Breast Cancer Patient
(P121) Trend in Age and Racial Disparities in the Receipt of Postlumpectomy Radiation Therapy for Stage I Breast Cancer: 2004–2009
(P122) Streamlining Referring Physicians Orders With ‘Reflex Testing’ Significantly Decreases Time to Resolution for Abnormal Screening Mammograms
(P123) National Trends in the Local Management of Early-Stage Paget Disease of the Breast
(P124) Effect of Inhomogeneity on Cardiac and Lung Dose in Partial-Breast Irradiation Using HDR Brachytherapy
(P125) Breast Cancer Outcomes With Anthracycline-Based Chemotherapy for Residual Disease Burden After Full-Dose Neoadjuvant Chemotherapy and Surgery Followed by Radiation Treatment
Related Videos
Pegulicianine-guided breast cancer surgery may allow practices to de-escalate subsequent radiotherapy, says Barbara Smith, MD, PhD.
Adrienne Bruce Shannon, MD, discussed ways to improve treatment and surgical outcomes for patients with dMMR gastroesophageal cancer.
Barbara Smith, MD, PhD, spoke about the potential use of pegulicianine-guided breast cancer surgery based on reports from the phase 3 INSITE trial.
Patient-reported symptoms following surgery appear to improve with the use of perioperative telemonitoring, says Kelly M. Mahuron, MD.
Treatment options in the refractory setting must improve for patients with resected colorectal cancer peritoneal metastasis, says Muhammad Talha Waheed, MD.
Although immature, overall survival data from the KEYNOTE-868 trial may support the use of pembrolizumab plus chemotherapy in patients with endometrial cancer.
Dostarlimab plus chemotherapy appears to yield favorable overall survival in patients with mismatch repair proficient endometrial cancer.
Some patients with large B-cell lymphoma may have to travel a great distance for an initial evaluation for CAR T-cell therapy.
Brian Slomovitz, MD, MS, FACOG discusses the use of new antibody drug conjugates for treating patients with various gynecologic cancers.
Education is essential to referring oncologists manage toxicities associated with CAR T-cell therapy for patients with large B-cell lymphoma.
Related Content